However, cetuximab, as the only FDA-approved anti-EGFR antibody in the US, has shown quite disappointing efficacy as monotherapy in HNSCC with a 10–30% response rate18–20. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.